Dr. Panayotis Ledakis, MD

Dr. Ledakis practices at Mercy Medical Center in Baltimore, Maryland, part of Mercy Medical Center.

Dr. Ledakis' NPI, 1649385634, was assigned on August 20, 2006. Dr. Ledakis holds Maryland license D047934.

Dr. Ledakis' primary practice is Mercy Medical Center, at 301 Saint Paul Place, Baltimore, MD 21202 in Baltimore City. The practice phone is (410) 332-9237.

Dr. Ledakis' primary practice is Mercy Medical Center in Baltimore, Maryland, part of Mercy Medical Center. Dr. Ledakis is also affiliated with The Johns Hopkins Hospital. The medical group on file is Mercy Personal Physicians Downtown. Dmand AI also links Dr. Ledakis to 1 more hospital, 2 group practices and clinics, 1 home health agency, 1 hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ledakis practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ledakis' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ledakis is licensed in Maryland.

CMS data shows 201,025 Medicare services from Dr. Ledakis across 42 procedure codes in 2024, for 1,099 Medicare patients. Medicare paid $1,798,063 for them.

CMS counts 1,099 Medicare patients who saw Dr. Ledakis in 2024. The largest group is 65 to 74, with 488 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ledakis' median patient age at 72, with 69% women.

In 2024, Dr. Ledakis wrote 660 Medicare Part D claims for 256 patients. 76% of them were for generic drugs. CMS names the drug for 355 of them, across 19 drugs with 11 or more claims each, at $505,769 in total drug cost. In 2023, CMS named 357 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 69 out of 100 for Dr. Ledakis for performance year 2024, reported individually. Dr. Ledakis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ledakis as offering telehealth.

Dmand AI links 11 papers to Dr. Ledakis, published from 2012 to 2025. 2022 was the busiest year, with 3. The most frequent topics are Appendiceal Neoplasms, Peritoneal Neoplasms and Cytoreduction Surgical Procedures. Dr. Ledakis has published most often in Eur J Surg Oncol. Dr. Ledakis' most frequent co-authors are Armando Sardi, MD, Carol Ann Nieroda, MD and Ekaterina Baron, MD.

CMS Open Payments shows 347 general payments to Dr. Ledakis from 51 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 42% of the total. ImmunoGen, Inc. paid the most, $7,580.